Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy by Dubey, D, Britton, J, McKeon, A, Ramberger, M, Waters, P, Irani, S

The B cell immunobiology that underlies CNS autoantibody-mediated diseases by Sun, B, Ramberger, M, O’Connor, KC, Bashford-Rogers, RJM, Irani, SR

International multicenter examination of MOG antibody assays by Reindl, M, Schanda, K, Woodhall, M, Ramberger, M, Leite, MI, Palace, J, Irani, SR, Waters, P

Screening for encephalitis-causing autoantibodies in serum and CSF of first-episode psychosis patients and controls by Theorell, J, Ramberger, M, Harrison, R, Mgbachi, V, Jacobson, L, Waters, P, Cervenka, S, Irani, SR, Piehl, F

Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy by Dubey, D, Britton, J, McKeon, A, Gadoth, A, Zekeridou, A, Chiriboga, SA, Devine, M, Cerhan, JH, Dunlay, K, Sagen, J, Ramberger, M, Waters, P, Irani, SR, Pittock, SJ

Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms by Ramberger, M, Berretta, A, Tan, JMM, Sun, B, Michael, S, Yeo, T, Theorell, J, Bashford-Rogers, R, Paneva, S, O'Dowd, V, Dedi, N, Topia, S, Griffin, R, Ramirez-Franco, J, El Far, O, Baulac, S, Leite, MI, Sen, A, Jeans, A, McMillan, D, Marshall, D, Anthony, D, Lightwood, D, Waters, P, Irani, SR